

Gennex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA Tel : +91-40-67334400 (30Lines), 23746451, Fax : +91-40-67334433 Email: info@gennexlab.com | www.gennexlab.com CIN : L24230TG1990PLCO11168

To

Ref: GLL/OC/2018-19/0053

Date: 14/02/2019.

To Dy. General Manager, **Bombay Stock Exchange Ltd.,** Phiroje Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Asst. Manager (Listing) **The Ahmedabad Stock Exchange Ltd.,** Kamdhenu Complex, Opp.Sahajanand College, Ahmedabad – 380 015.

То

The Secretary **The Calcutta Stock Exchange Association Ltd.,** 7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject	:	Submission of Standalone and Consolidated Un-Audited Limited Reviewed Financial
		Result as per Ind-As for the 3 rd Quarter and Nine Months Ended
		31 st December, 2018.
Reference	:	Security ID : GENNEX & Script Code – 531739

We enclose the Standalone and Consolidated Un-Audited Financial Results as per Ind-AS for the 3rd Quarter and Nine Months ended 31st December, 2018 of the Company together with Limited Review Report thereon pursuant to the Regulation 33(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which was approved and taken on records by the Board of Directors at its Meeting held today i.e., 14.02.2019.

The Board Meeting commenced at 04:30 p.m. and concluded at 06:45 p.m.

We would be obliged if you could take the above on records.

Thanking You,

Yours faithfully, For Gennex Laboratories Ltd.,

porato, Authorised Signatory Hyderaba Encl: as above





GENNEX LABORATORIES LIMITED

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2018

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168

PART - I	1. L. L. L. L.
Statement of	

E

01.	ent of standalone Unaudited Financial Results for the Quarter and Nine mon	and chuck of Dec	cember, 2018				(Rs. in lakhs
No.	Particulars		Quarter Ended			Nine Months Ended	
		31.12.2018	30.09.2018	31.12.2017	31.12.2018 31.12.2017		Year ended 31.03.2018
1	Income from Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	(a) Revenue from Operations				((onaudited)	(Audited)
	(b) Other operating Income	1521.55	1078.16	1188.61	3544.20	2020.04	
		20.52	18.27	12.82	53.22	3030.61	4377.88
	Total Income from operations (net)				55.22	17.65	90.36
	(iet)	1542.07	1096.43	1201.43	2505 10		
2	Expenses			1201.43	3597.42	3048.26	4468.24
	(a) Cost of material consumed						
	(b) Purchassa of at a training	939.82	696.09	740 50	1.1.1.1.1.1.1.1		
	(b) Purchases of stock-in-trade	0.00		719.56	2254.89	1793.31	2567.72
	(c) Changes in inventories of finished goods,	0.00	2.93	13.51	2.93	13.51	30.01
	work-in-progress and stock-in-trade	-34.60	00.50				
	(d) Employee benefit expense	167.93	-88.53	-3.50	-220.30	-56.23	75.42
	(f) Finane Cost		135.40	122.92	431.42	370.46	554.58
	(g) Depreciation and amortisation expense	25.65	16.45	15.23	59.09	49.44	73.11
	(h) Other expenses	30.51	24.48	28.10	79.01	73.36	92.18
		330.83	261.46	255.15	812.93	679.27	930.88
	Total expenses					010.21	930.88
		1460.14	1048.28	1150.97	3419.97	2923.12	1200.0
	Profit(+)/Loss(-) from operations before any still				0410.07	2923.12	4323.9
	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2) Exceptional items	81.93	48.15	50.46	177.45	105.11	
	Profit(+)/Loss(-) before tax (3+4)	0.00	0.00	0		125.14	144.34
	Taxes of earlier years	81.93	48.15	50.46	0.00	-1	-1
	Current Tax	0.00	0	-19.60	177.45	126.14	145.34
			°	-13.60	0	-20.41	-61.13
	Deferred tax(benefit/expense)				A Paul A		-35.00
	Total Tax expense	0.00	0.00	10.00			34.37
' Ľ	Net movement in regulatory deferral account balances related to	0.00	0.00	-19.60	0.00	-20.41	-61.76
· ·	Tont of loss and the related deffered tax movement	0					
F	Profit(+)/Loss(-) for the period from continuing operation (5-9)	81.93	0	0	0	0	0
		01.95	48.15	30.86	177.45	105.73	83.58
F	Profit(+)/Loss(-) from discontinued operations before tax						
1	ax expense of discontinued operations					Distantia di	
	let Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
s	share of Profit(loss) of associates and thin the	0.0	0.0	0.0	0.0	0.0	
	share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
T	otal profit(loss) for period				0.0	0.0	0.0
lo	ther comprehensive l	81.93	48.15	30.86	177.45	405 70	
N	other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	105.73	83.58
P	let profit(loss) for period	81.93	48.15	30.86		0.00	0
17	aid-up Equity Share Capital		10.10	50.00	177.45	105.73	83.58
10	ace value Rs. 1 each Equity Share)	1265.03	1265.03	1005.00			
	ther Equity	1200.00	1205.03	1265.03	1265.03	1265.03	1265.03
E	arning Per Equity Share (EPS) (Face value of Rs 1 per Share)						1911.72
(of Rs. 1 each) (not annualised) :						
(a) Basic		1				
(1) Diluted	0.065	0.038	0.024	0.140	0.084	0.066
		0.065	0.038	0.024	0.140	0.084	0.066

OTES to the results: 1)

The above standalone unaudited financial results for the nine months ended 31st December 2018 have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on February 14, 2019 and the limited review of the same has been carried out by the

The standalone financial results have been prepared in accordance with the India Accounting Standards (Ind AS) prescribed under Section 133 of the Companies 2) Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and 3)

Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year. 4)

Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.

The Company has only one reporable segment namely " Bulk Drugs, Biotech Products and Intermediates". 5)

ace: Hyderabad ate: 14.02.2019

aboratori fland Connex / Hyderabad

For and on behalf of the Board For Gennex Laboratories Limited sd/-

Arihant Baid Managing Director

Chartered Accountants PPKG & Co

To

5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.
Ph : +91-40-23205049, 66132176, 48517622
email : giri@ppkg.com • www.batgach.com

LIMITED REVIEW REPORT

The Board of Directors, GENNEX LABORATORIES LIMITED, Hyderabad.

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of GENNEX LABORATORIES LIMITED ("the company") for the Quarter/ Nine Months ended 31st December, 2018 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This said statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other accounting principles generally accepted in India and has been approved by its Board of Directors. Our responsibility is to issue a report on the Financial Statement based on our review.

We conducted our review in accordance with the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion





Associate Office at : • AHMEDABAD • ASSAM • BANGALORE • CHENNAI • DELHI • GUWAHATI • JAIPUR • KOLKATA • MUMBAI • TRIVANDRUM Based on our review conducted as above and subject to the non-presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

G&

Place: Hyderabad Date: 14/02/2019 For PPKG & CO Chartered Accountants FRN No. 009655S

Comiva 0

GIRDHARI LAL TOSHNIWAL) M.No. 205140



GENNEX LABORATORIES LIMITED

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2018 Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com CIN: L24230TG1990PLC011168

01	ent of Consolidated Unaudited Financial Results for the Quarter and Nine m	antha a tara							
SI. No.	ement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2018								
NO.	Particulars		Quarter Ende	d	Nine Mor	ths Ended	(Rs. in lakhs)		
4		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	Year ende		
1	Income from Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		31.03.201		
	(a) Revenue from Operations			, , , , , , , , , , , , , , , , , , , ,	(onaddited)	(Unaudited)	(Audited)		
	(b) Other operating Income	1521.55	1078.16	1188.61	3544.20				
	- 19 방법 · 2013 · 2018 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 2014 · 201	20.52	18.27	12.82		3030.61	4377.88		
	Total Income from operations (net)			12.02	53.22	17.65	90.36		
		1542.07	1096.43	1201.43	0.505.10				
2	Expenses			1201.43	3597.42	3048.26	4468.24		
	(a) Cost of material consumed								
	(b) Purchases of stock-in-trade	939.82	696.09			State of the			
	(c) Changes in investorial	0.00		719.56	2254.89	1793.31	2567.72		
	(c) Changes in inventories of finished goods,	0.00	2.93	13.51	2.93	13.51	30.01		
	work-in-progress and stock-in-trade	-34.60	00.50			1000			
	(d) Employee benefit expense (f) Finane Cost	167.93	-88.53	-3.50	-220.30	-56.23	75.42		
		25.65	135.40	122.92	431.42	370.46	554.58		
	(g) Depreciation and amortisation expense	30.51	16.45	15.23	59.09	49.44	73.11		
	(h) Other expenses		24.48	28.10	79.01	73.36	92.18		
	우리는 물건물건을 하는 것 같아. 그는 것 같아. 이렇게 물건을 다 나는 것	330.83	261.46	255.15	812.93	679.27			
	Total expenses					010.27	930.88		
	2011년 2017년 1월 2019년 1 1월 2019년 1월 2	1460.14	1048.28	1150.97	3419.97	2923.12	1000.0		
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)				0110.07	2923.12	4323.9		
		81.93	48.15	50.46	177.45	100.11			
5	Profit(+)/Loss(-) before tax (3+4)	0.00	0.00	0	0.00	125.14	144.34		
5	Taxes of earlier years	81.93	48.15	50.46	177.45	-1	-1		
	Current Tax	0.00	0	-19.60		126.14	145.34		
	Deferred tax(benefit/expense)			10.00	0	-20.41	-61.13		
·	Total Tax expense						-35.00		
	Net movement in regulatory default	0.00	0.00	-19.60			34.37		
	Net movement in regulatory deferral account balances related to		0.00	-19.60	0.00	-20.41	-61.76		
	Profit or loss and the related deffered tax movement	0	0						
ľ	Profit(+)/Loss(-) for the period from continuing operation (5-9)	81.93	48.15	0	0	0	0		
		01.00	40.15	30.86	177.45	105.73	83.58		
	Profit(+)/Loss(-) from discontinued operations before tax								
	an expense of discontinued operations								
	Net Profit(loss) for the period from discontinued exercise	0.0	0.0	0.0	0.0	0.0	0.0		
	indie of Front(1055) of associates and loint Vontures	0.0	0.0	0.0	0.0	0.0			
	source include	0.0	0.0	0.0	0.0	0.0	0.0		
Т	otal profit(loss) for period					0.0	0.0		
	ther comprehensive Income net of taxes	81.93	48.15	30.86	177.45	105.73			
N	let profit(loss) for period	0.00	0.00	0.00	0.00	0.00	83.58		
P	aid-up Equity Share Capital	81.93	48.15	30.86	177.45		0		
(F	ace value Rs. 1 each Equity Share)				177.45	105.73	83.58		
lo	ther Equity	1265.03	1265.03	1265.03	1005 00				
E	arning Per Equity Share (EDG) (5			1203.03	1265.03	1265.03	1265.03		
1	arning Per Equity Share (EPS) (Face value of Rs 1 per Share)						1911.72		
1,	(not annualised) :		1						
) Basic	0.065	0.020			1. S. S. S. S. S.			
()) Diluted		0.038	0.024	0.140	0.084	0.066		
		0.065	0.038	0.024	0.140	0.084	0.066		

NOTES to the results:

The above Consolidted unaudited financial results for the nine months ended 31st December 2018 have been reviewed by the Audit Committee of the Board of 1) Directors and taken on record at the meeting of Board of Directors held on February 14, 2019 and the limited review of the same has been carried out by the

The consolidated financial results have been prepared in accordance with the India Accounting Standards (Ind AS) prescribed under Section 133 of the 2) Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the 3)

Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year. 4)

Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.

The Company has only one reporable segment namely " Bulk Drugs, Biotech Products and Intermediates". 5) The Company is having one associate by name M/s. Deccan Remedies Limited which has not yet commenced its operations 6)

ace: Hyderabad ate: 14.02.2019

aboratorio Jebanig xeuuex Hyderabad

For and on behalf of the Board For Gennex Laboratories Limited sd/-

Arihant Baid **Managing Director**

Chartered Accountants PPKG & Co

То

5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.
Ph : +91-40-23205049, 66132176, 48517622 email : giri@ppkg.com

LIMITED REVIEW REPORT

The Board of Directors, GENNEX LABORATORIES LIMITED, Hyderabad.

We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of GENNEX LABORATORIES LIMITED ("the company") and its Associate for the Quarter/ Nine Months ended 31st December, 2018 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This said statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other accounting principles generally accepted in India and has been approved by its Board of Directors. Our responsibility is to issue a report on the Financial Statement based on our review.

We conducted our review in accordance with the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





Associate Office at : • AHMEDABAD • ASSAM • BANGALORE • CHENNAI • DELHI • GUWAHATI • JAIPUR • KOLKATA • MUMBAI • TRIVANDRUM Based on our review conducted as above and subject to the non-presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

KGR

Place: Hyderabad Date: 14/02/2019 For PPKG & CO Chartered Accountants FRN No. 009655S

lesin

(GIRDHARI LAL TOSHNIWAL) M.No. 205140